share_log

For The FY24, At Constant Exchange Rates, Molecular Partners Reiterates Its Guidance For Total Expenses Of CHF 65–70 Million. ~CHF 7 Million Of This Will Be Non-Cash Effective Costs For Share-Based Payments, Pension Accounting And Depreciation. This...

For The FY24, At Constant Exchange Rates, Molecular Partners Reiterates Its Guidance For Total Expenses Of CHF 65–70 Million. ~CHF 7 Million Of This Will Be Non-Cash Effective Costs For Share-Based Payments, Pension Accounting And Depreciation. This...

在相同的匯率下,對於FY24,Molecular Partners重申其總費用預計爲6500-7000萬瑞士法郎。其中約700萬瑞士法郎將用於非現金有效成本,包括基於股份支付、養老金會計和折舊。這...
Benzinga ·  11/01 04:07

For The FY24, At Constant Exchange Rates, Molecular Partners Reiterates Its Guidance For Total Expenses Of CHF 65–70 Million. ~CHF 7 Million Of This Will Be Non-Cash Effective Costs For Share-Based Payments, Pension Accounting And Depreciation. This Guidance Does Not Include Any Potential Receipts From R&D Collaborators

對於FY24,在恒定匯率下,Molecular Partners重申其在瑞士法郎65-7000萬瑞士法郎的總費用指導。其中約700萬瑞士法郎將用於股份支付、養老金會計和折舊等非現金有效成本。此指導不包括來自研發合作伙伴的潛在收入。

Financial and Business Outlook

財務和業務展望

For the full year 2024, at constant exchange rates, the Company reiterates its guidance for total expenses of CHF 65–70 million. Approximately CHF 7 million of this will be non-cash effective costs for share-based payments, pension accounting and depreciation. This guidance does not include any potential receipts from R&D collaborators.

對於2024年全年,在恒定匯率下,該公司重申其在瑞士法郎65-7000萬瑞士法郎的總費用指導。其中約700萬瑞士法郎將用於股份支付、養老金會計和折舊等非現金有效成本。此指導不包括來自研發合作伙伴的潛在收入。

With CHF 143.6 million in cash and short-term time deposits and no debt as of September 30, 2024, the Company expects to be funded into 2027, excluding any potential receipts from R&D collaborators.

截至2024年9月30日,公司現金及短期存款金額爲14360萬瑞士法郎,無債務,預計資金將持續到2027年,不包括來自研發合作伙伴的潛在收入。

On October 25, 2024, Molecular Partners announced the pricing of an underwritten offering in the US of 3'642'988 American Depositary Shares (ADSs) representing 3'642'988 ordinary shares at an offering price of USD 5.49 per ADS. The total gross proceeds amount to approximately USD 20 million. The offering included participation from a new investor HBM Healthcare Investments Ltd, which is a leading healthcare investor, as well as multiple existing investors. Leerink Partners and TD Cowen acted as joint bookrunning managers for the offering. LifeSci Capital acted as lead manager for the offering, and Zürcher Kantonalbank (ZKB) served as settlement agent. Molecular Partners currently intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, for development and expansion of its radiopharmaceutical pipeline and platform (Radio-DARPin Therapeutics) and for working capital and other general corporate purposes. Subsequent to the offering, the Company has (proforma) cash and short-term time deposits in the amount of CHF 158 million, with 40,363,095 issued shares.

2024年10月25日,Molecular Partners宣佈在美國發行的3,642,988股美國存托股票(ADS)的定價,代表3,642,988股普通股,發行價格爲每股5.49美元。總共的募集資金約爲2000萬美元。本次發行包括來自新投資者HBm Healthcare Investments Ltd的參與,後者是一家領先的醫療保健投資者,以及多家現有投資者。Leerink Partners和TD Cowen擔任本次發行的聯席主承銷商。LifeSci Capital擔任本次發行的首席承銷商,蘇黎世州立銀行(ZKB)擔任結算代理。Molecular Partners目前打算使用本次發行的淨收益與現有的現金及現金等價物一起,用於其放射藥物管線和平台(Radio-DARPin療法)的發展和擴張,以及用於運營資本和其他一般企業用途。發行後,公司擁有(經過調整後的)現金和短期存款金額爲15800萬瑞士法郎,發行股份爲40,363,095股。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論